Peripheral neuropathy induced by microtubule-stabilizing agents

Journal of Clinical Oncology

Volumn 24, Issue 10, 2006, Pages 1633-1642

  Lee, James J ^a   Swain, Sandra M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AM 424; AMIFOSTINE; AMITRIPTYLINE; BMS 310705; CARBOPLATIN; CISPLATIN; DIMESNA; DOCETAXEL; EPIRUBICIN; EPOTHILONE B; EPOTHILONE D; EPOTHILONE DERIVATIVE; GABAPENTIN; GLUTAMINE; IXABEPILONE; LAMOTRIGINE; LEUKEMIA INHIBITORY FACTOR; LEVACECARNINE; PACLITAXEL; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; ALBUMINOID; ANTINEOPLASTIC AGENT; NEUROPROTECTIVE AGENT; TUBULIN MODULATOR;

ARTHRALGIA; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG WITHDRAWAL; ELECTROPHYSIOLOGY; HUMAN; MORBIDITY; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUROPATHIC PAIN; NEUROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PSYCHOMETRY; REVIEW; RISK FACTOR; SENSORY NEUROPATHY; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; MICROTUBULE; PAIN;

ALBUMINS; ANIMALS; ANTINEOPLASTIC AGENTS; EPOTHILONES; HUMANS; MICROTUBULES; NEUROPROTECTIVE AGENTS; PACLITAXEL; PAIN; PERIPHERAL NERVOUS SYSTEM DISEASES; RISK FACTORS; TUBULIN MODULATORS;

EID: 33645736326     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.0543     Document Type: Review

References (131)

1. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 277: 665-667, 1979
2. Yvon AM, Wadsworth P, Jordan MA: Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 10:947-959, 1999
3. O'Shaughnessy J, Tjulandin S, Davidson N, et al: ABI-007 (ABRAXANE), a nanoparticle albumin-bound (nab) paclitaxel demonstrates superior efficacy vs taxol in MBC: A phase III trial. 26th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 3-6, 2003 (abstr 44)
4. O'Shaughnessy J, Blum J, Sandbach J, et al: Weekly nanoparticle albumin paclitaxel (Abraxane) results in long-term disease control in patients with taxane-refractory metastatic breast cancer. 27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-11, 2004 (abstr 1070)
5. Ibrahim NK, Samuels B, Page R, et al: Nanoparticle paclitaxel (ABI-007) in metastatic breast cancer (MBC): Efficacy and evidence of dose-dependent activity in two multicenter phase II studies. Proc Am Soc Clin Oncol 21:53a, 2002 (abstr 209)
6. Gradishar WJ, Tjulandin S, Davidson N, et al: Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794-7803, 2005
7. de Jonge M, Verweij J: The epothilone dilemma. J Clin Oncol 23:9048-9050, 2005
8. Von Hoff DD: The taxoids: Same roots, different drugs. Semin Oncol 24:S13-3-S13-10, 1997
9. Goodin S, Kane MP, Rubin EH: Epothilones: Mechanism of action and biologic activity. J Clin Oncol 22:2015-2025, 2004
10. Winer EP, Berry DA, Woolf S, et al: Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B trial 9342. J Clin Oncol 22:2061-2068, 2004
11. Seidman AD, Berry D, Cirrincione C, et al: CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol 22:6s, 2004 (suppl 14; abstr 512)
12. Smith RE, Brown AM, Mamounas EP, et al: Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-26. J Clin Oncol 17:3403-3411, 1999
13. Ravdin P, Erban J, Overmoyer B, et al: Phase III comparison of docetaxel (D) and paclitaxel (P) in patients with metastatic breast cancer (MBC). Eur J Cancer 1:S201, 2003 (suppl 1, abstr 670)
14. Paridaens R, Biganzoli L, Bruning P, et al: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer randomized study with cross-over. J Clin Oncol 18:724-733, 2000
15. 2 as second line chemotherapy in advanced breast cancer. 25th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 11-14, 2002 (abstr 327)
16. Chan S, Friedrichs K, Noel D, et al: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17:2341-2354, 1999
17. Nabholtz JM, Senn HJ, Bezwoda WR, et al: Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy: 304 study group. J Clin Oncol 17:1413-1424, 1999
18. Kruijtzer CMF, Verweij J, Schellens JH, et al: Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: Results of a compassionate use program in The Netherlands. Anticancer Drugs 11:249-255, 2000
19. Blum JL, Savin MA, Edelman G, et al: Long term disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel. J Clin Oncol 22:13s, 2004 (suppl 14; abstr 543)
20. Low JA, Wedam SB, Lee JJ, et al: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 23:2726-2734, 2005
21. Zhuang SH, Menefee M, Kotz H, et al: A phase II clinical trial of BMS-247550 (ixabepilone), a microtubule-stabilizing agent in renal cell cancer. J Clin Oncol 22:394s, 2004 (suppl 14; abstr 4550)
22. Galsky MD, Small EJ, Oh WK, et al: Multiinstitutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 23:1439-1446, 2005
23. Thomas E, Tabernero J, Fornier M, et al: A phase II study of the epothilone B analog BMS-247550 in patients (pts) with taxane-resistant metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 22:8, 2003 (abstr 30)
24. Roche HH, Cure H, Bunnell C, et al: A phase II study of epothilone analog BMS-247550 in patients (pts) with metastatic breast cancer (MBC) previously treated with an anthracycline. Proc Am Soc Clin Oncol 22:18, 2003 (abstr 69)
25. Hussain M, Tangen CM, Lara PN Jr, et al: Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: A Southwest Oncology Group trial S0111. J Clin Oncol 23:8724-8729, 2005
26. Eng C, Kindler HL, Nattam S, et al: A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. Ann Oncol 15:928-932, 2004
27. Hussain A, Dipaola RS, Baron AD, et al: A phase IIa trial of weekly EPO906 in patients with hormone-refractory prostate cancer (HPRC). J Clin Oncol 22:397s, 2004 (suppl 14; abstr 4563)
28. Piro LD, Rosen LS, Parson M, et al: KOS-862 (epothilone D): A comparison of two schedules in patients with advanced malignancies. Proc Am Soc Clin Oncol 22:135, 2003 (abstr 539)
29. Yee L, Lynch T, Villalona-Calero M, et al: A phase II study of KOS-862 (epothilone D) as second-line therapy in non-small cell lung cancer. J Clin Oncol 23:652s, 2005 (abstr 7127)
30. Overmoyer B, Waintraub S, Kaufman PA, et al: Phase II trial of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer. J Clin Oncol 23:72s, 2005 (suppl 16; abstr 778)
31. Mekhail T, Chung C, Holden S, et al: Phase I trial of novel epothilone B analog BMS-310705 IV q 21 days. Proc Am Soc Clin Oncol 22:129, 2003 (abstr 515)
32. Davis ID, Kiers L, Macgregor L, et al: A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, Emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clin Cancer Res 11:1890-1898, 2005
33. Jacobson SD, Loprinzi CL, Sloan JA, et al: Glutamine does not prevent paclitaxel-associated myalgias and arthralgias. J Support Oncol 1:274-278, 2003
34. Vahdat L, Papadopoulos K, Lange D, et al: Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res 7:1192-1197, 2001
35. Openshaw H, Beamon K, Synold TW, et al: Neurophysiological study of peripheral neuropathy after high-dose paclitaxel: Lack of neuroprotective effect of amifostine. Clin Cancer Res 10:461-467, 2004
36. De Vos FY, Bos AM, Schaapveld M, et al: A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma. Gynecol Oncol 97:60-67, 2005
37. Barohn RJ: Approach to peripheral neuropathy and neuronopathy. Semin Neurol 18:7-18, 1998
38. Theiss C, Meller K: Taxol impairs anterograde axonal transport of microinjected horseradish peroxidase in dorsal root ganglia neurons in vitro. Cell Tissue Res 299:213-224, 2000
39. Nakata T, Yorifuji H: Morphological evidence of the inhibitory effect of Taxol on the fast axonal transport. Neurosci Res 35:113-122, 1999
40. Roytta M, Horwitz SB, Raine CS: Taxol-induced neuropathy: Short-term effects of local injection. J Neurocytol 13:685-701, 1984
41. Cavaletti G, Cavalletti E, Montaguti P, et al: Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. Neurotoxicology 18:137-145, 1997
42. Sahenk Z, Barohn R, New P, et al: Taxol neuropathy: Electrodiagnostic and sural nerve biopsy findings. Arch Neurol 51:726-729, 1994
43. Wiernik PH, Schwartz EL, Strauman JJ, et al: Phase I clinical and pharmacokinetic study of Taxol. Cancer Res 47:2486-2493, 1987
44. Nabholtz JM, Gelmon K, Bontenbal M, et al: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858-1867, 1996
45. Mielke S, Sparreboom A, Steinberg SM, et al: Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res 11: 4843-4850, 2005
46. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994
47. Jones SE, Erban J, Overmoyer B, et al: Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23:5542-5551, 2005
48. Lee JJ, Low JA, Croarkin E, et al: Evaluation of neuropathy in breast cancer patients treated with ixabepilone. J Clin Oncol 23:42s, 2005 (suppl 16; abstr 657)
49. Rowinsky EK, Eisenhauer EA, Chaudhry V, et al: Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:1-15, 1993
50. Rowinsky EK, Chaudhry V, Cornblath DR, et al: Neurotoxicity of Taxol. J Natl Cancer Inst Monogr 15:107-115, 1993
51. Gogas H, Shapiro F, Aghajanian C, et al: The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer. Gynecol Oncol 61:22-26, 1996
52. Fountzilas G, Kalofonos HP, Dafni U, et al: Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: A phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 15:1517-1526, 2004
53. Chaudhry V, Rowinsky EK, Sartorius SE, et al: Peripheral neuropathy from Taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies. Ann Neurol 35:304-311, 1994
54. Akerley W, Herndon JE, Egorin MJ, et al: Weekly, high-dose paclitaxel in advanced lung carcinoma: A phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer 97:2480-2486, 2003
55. Weimer LH: Medication-induced peripheral neuropathy. Curr Neurol Neurosci Rep 3:86-92, 2003
56. Wang MS, Fang G, Culver DG, et al: The WldS protein protects against axonal degeneration: A model of gene therapy for peripheral neuropathy. Ann Neurol 50:773-779, 2001
57. Wang MS, Davis AA, Culver DG, et al: WldS mice are resistant to paclitaxel (Taxol) neuropathy. Ann Neurol 52:442-447, 2002
58. Wang M, Wu Y, Culver DG, et al: The gene for slow Wallerian degeneration (Wld(s)) is also protective against vincristine neuropathy. Neurobiol Dis 8:155-161, 2001
59. Aplenc R, Glatfelter W, Han P, et al: CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia. Br J Haematol 122: 240-244, 2003
60. Valero V, Holmes FA, Walters RS, et al: Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13:2886-2894, 1995
61. New PZ, Jackson CE, Rinaldi D, et al: Peripheral neuropathy secondary to docetaxel (Taxotere). Neurology 46:108-111, 1996
62. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991
63. Hilkens PH, Verweij J, Stoter G, et al: Peripheral neurotoxicity induced by docetaxel. Neurology 46:104-108, 1996
64. Martoni A, Zamagni C, Gheka A, et al: Antihistamines in the treatment of Taxol-induced paroxystic pain syndrome. J Natl Cancer Inst 85:676, 1993
65. Lorenz E, Hagen B, Himmelmann A, et al: A phase II study of biweekly administration of paclitaxel in patients with recurrent epithelial ovarian cancer. Int J Gynecol Cancer 9:373-376, 1999
66. Freilich RJ, Balmaceda C, Seidman AD, et al: Motor neuropathy due to docetaxel and paclitaxel. Neurology 47:115-118, 1996
67. Warner E: Neurotoxicity of cisplatin and Taxol. Int J Gynecol Cancer 5:161-169, 1995
68. Postma TJ, Vermorken JB, Liefting AJ, et al: Paclitaxel-induced neuropathy. Ann Oncol 6:489-494, 1995
69. Ravdin PM, Burris HA III, Cook G, et al: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879-2885, 1995
70. National Cancer Institute: Common Toxicity Criteria version 2.0. http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf
71. National Cancer Institute: Common Terminology Criteria for Adverse Events v 3.0. http://ctep.cancer.gov/forms/CTCAEv3.pdf
72. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
73. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47: 207-214, 1981
74. Postma TJ, Heimans JJ: Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol 11:509-513, 2000
75. Maser RE, Nielsen VK, Bass EB, et al: Measuring diabetic neuropathy: Assessment and comparison of clinical examination and quantitative sensory testing. Diabetes Care 12:270-275, 1989
76. Postma TJ, Heimans JJ, Muller MJ, et al: Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 9:739-744, 1998
77. Brundage MD, Pater JL, Zee B: Assessing the reliability of two toxicity scales: Implications for interpreting toxicity data. J Natl Cancer Inst 85:1138-1148, 1993
78. Cella D, Peterman A, Hudgens S, et al: Measuring the side effects of taxane therapy in oncology: The Functional Assessment of Cancer Therapy-Taxane (FACT-taxane). Cancer 98:822-831, 2003
79. Cull A, Howat S, Greimel E, et al: Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: A progress report. Eur J Cancer 37:47-53, 2001
80. Monk BJ, Huang HQ, Cella D, et al: Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: A Gynecologic Oncology Group study. J Clin Oncol 23:4617-4625, 2005
81. Wenzel L, Huang HQ, Monk BJ, et al: Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 23:5605-5612, 2005
82. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
83. Fossa SD, de Wit R, Roberts JT, et al: Quality of life in good prognosis patients with metastatic germ cell cancer: A prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer study group (30941/TE20). J Clin Oncol 21:1107-1118, 2003
84. Postma TJ, Aaronson NK, Heimans JJ, et al: The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. Eur J Cancer 41:1135-1139, 2005
85. Olney RK: Clinical trials for polyneuropathy: The role of nerve conduction studies, quantitative sensory testing, and autonomic function testing. J Clin Neurophysiol 15:129-137, 1998
86. Forsyth PA, Balmaceda C, Peterson K, et al: Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neurooncol 35:47-53, 1997
87. Kamei N, Yamane K, Nakanishi S, et al: Effectiveness of Semmes-Weinstein monofilament examination for diabetic peripheral neuropathy screening. J Diabetes Complications 19:47-53, 2005
88. Padua L, Aprile I, Saponara C, et al: Multiperspective assessment of peripheral nerve involvement in diabetic patients. Eur Neurol 45:214-221, 2001
89. Perkins BA, Olaleye D, Zinman B, et al: Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care 24:250-256, 2001
90. Jebsen RH, Taylor N, Trieschmann RB, et al: An objective and standardized test of hand function. Arch Phys Med Rehabil 50:311-319, 1969
91. Casanova JE, Casanova JS, Young MJ: Hand function in patients with diabetes mellitus. South Med J 84:1111-1113, 1991
92. Meneilly GS, Cheung E, Tessier D, et al: The effect of improved glycemic control on cognitive functions in the elderly patient with diabetes. J Gerontol 48:M117-M121, 1993
93. Trites R: Neuropsychological Test Manual. Ottawa, Ontario, Canada, Royal Ottawa Hospital, 1977
94. Ruff RM, Parker SB: Gender- and age-specific changes in motor speed and eye-hand coordination in adults: Normative values for the Finger Tapping and Grooved Pegboard Tests. Percept Mot Skills 76:1219-1230, 1993
95. Low J, Croarkin E, Parks R, et al: Assessment of neurotoxicity in patients receiving BMS-247550 for metastatic breast cancer. 26th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 3-6, 2003 (abstr 358)
96. Lipton RB, Apfel SC, Dutcher JP, et al: Taxol produces a predominantly sensory neuropathy. Neurology 39:368-373, 1989
97. Fazio R, Quattrini A, Bolognesi A, et al: Docetaxel neuropathy: A distal axonopathy. Acta Neuropathol (Berl) 98:651-653, 1999
98. Davidson NG: Single-agent paclitaxel as first-line treatment of metastatic breast cancer: The British experience. Semin Oncol 23:6-10, 1996
99. Seidman AD, Hudis CA, Albanel J, et al: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16:3353-3361, 1998
100. Nguyen VH, Lawrence HJ: Use of gabapentin in the prevention of taxane-induced arthralgias and myalgias. J Clin Oncol 22:1767-1769, 2004
101. van Deventer H, Bernard S: Use of gabapentin to treat taxane-induced myalgias. J Clin Oncol 17:434-435, 1999
102. Hilpert F, Stahle A, Tome O, et al: Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel- based chemotherapy: A double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group. Support Care Cancer 13:797-805, 2005
103. Lorusso D, Ferrandina G, Greggi S, et al: Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol 14:1086-1093, 2003
104. Moore DH, Donnelly J, McGuire WP, et al: Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: A phase II study of the Gynecologic Oncology Group. J Clin Oncol 21:4207-4213, 2003
105. Sevelda P, Sevelda U, Denison U, et al: Cytoprotection of amifostine (A) in ovarian cancer patients receiving paclitaxel/carboplatin (PC) first line chemotherapy in a multicenter phase III trial. J Clin Oncol 22:454s, 2004 (suppl 14; abstr 5021)
106. Leong SS, Tan EH, Fong KW, et al: Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol 21:1767-1774, 2003
107. Gelmon K, Eisenhauer E, Bryce C, et al: Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol 17:3038-3047, 1999
108. Socinski MA, Tynan M, Natoli S, et al: Phase II trial of paclitaxel (P), carboplatin (C) and amifostine in stage IV non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 18, 1999 (abstr 2015)
109. Robinson J, Akerley W, Safran H, et al: High dose weekly paclitaxel (P) and amifostine (as a neuroprotectant) for advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 18, 1999 (abstr 2337)
110. National Institutes of Health: Amifostine in treating peripheral neuropathy caused by paclitaxel in patients with solid tumors. http://clinicaltrials.gov/ct/show/NCT00078845
111. Takeda K, Negoro S, Matsui K, et al: Phase I safety and pharmacokinetic trial of BNP7787 in patients receiving cisplatin (CDDP) and paclitaxel (PTX) for advanced non-small cell lung cancer (NSCLC): An Osaka phase I study group trial. Proc Am Soc Clin Oncol 21:114a, 2002 (abstr 453)
112. National Institutes of Health: Evaluation of BNP7787 for the prevention of neurotoxicity in metastatic breast cancer patients receiving weekly paclitaxel. http://dinicaltrials.gov/ct/show/NCT00039780?order=1
113. National Institutes of Health: Docetaxel and cisplatin with or without dimesna in treating patients with stage IIIB or stage IV non-small cell lung cancer. http://clinicaltrials.gov/ct/show/NCT00077311
114. Davis ID, Kiers L, Quinn M, et al: A randomized, double-blinded, placebo-controlled phase II trial to determine the safety and efficacy of AM424 (emfilermin, rhLIF) in the prevention of chemotherapy-induced peripheral neuropathy (CIPN). Proc Am Soc Clin Oncol 22:740, 2003 (abstr 2976)
115. Bianchi G, Vitali G, Caraceni A, et al: Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer 41:1746-1750, 2005
116. Maestri A, De Pasquale Ceratti A, Cundari S, et al: A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori 91:135-138, 2005
117. Stubblefield MD, Vahdat LT, Balmaceda CM, et al: Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: A clinical and electrophysiologic study. Clin Oncol (R Coll Radiol) 17:271-276, 2005
118. Argyriou AA, Chroni E, Koutras A, et al: Vitamin E for prophylaxis against chemotherapy-induced neuropathy: A randomized controlled trial. Neurology 64:26-31, 2005
119. National Institutes of Health: Lamotrigine in treating peripheral neuropathy caused by chemotherapy in patients with cancer. http:// clinicaltrials.gov/ct/show/NCT00068445
120. Santini V: Amifostine: Chemotherapeutic and radiotherapeutic protective effects. Expert Opin Pharmacother 2:479-489, 2001
121. Hilpert F, Staehle A, Oliver T, et al: Neuroprotection with amifostine in 1st-line treatment of advanced ovarian cancer with carboplatin/taxane-based chemotherapy: A double-blind, placebo-controlled, randomized phase II-study of the AGO Ovarian Cancer Study Group. Proc Am Soc Clin Oncol 22:448, 2003 (abstr 1801)
122. Hensley ML, Schuchter LM, Lindley C, et al: American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 17:3333-3355, 1999
123. Schuchter LM, Hensley ML, Meropol NJ, et al: 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 20:2895-2903, 2002
124. Pendyala L, Schwartz G, Smith P, et al: Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy. Cancer Chemother Pharmacol 51:376-384, 2003
125. Hausheer FH, Kochat H, Parker AR, et al: New approaches to drug discovery and development: A mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent. Cancer Chemother Pharmacol 52:S3-S15, 2003 (suppl 1)
126. Boven E, Westerman M, van Groeningen CJ, et al: Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule. Br J Cancer 92:1636-1643, 2005
127. Boyle FM, Wheeler HR, Shenfield GM: Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate. J Neurooncol 41:107-116, 1999
128. Weijl NI, Hopman GD, Wipkink-Bakker A, et al: Cisplatin combination chemotherapy induces a fall in plasma antioxidants of cancer patients. Ann Oncol 9:1331-1337, 1998
129. Bove L, Picardo M, Maresca V, et al: A pilot study on the relation between cisplatin neuropathy and vitamin E. J Exp Clin Cancer Res 20:277-280, 2001
130. Miller ER III, Pastor-Barriuso R, Dalal D, et al: Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142:3746, 2005
131. National Institutes of Health. Evaluation of BNP7787 for the prevention of neurotoxicity in metastatic breast cancer patients receiving weekly paclitaxel. http://clinicaltrials.gov/ct/show/NCT00039780